Eleven genetic variants in inflammation and angiogenesis pathways are significantly associated with diabetic nephropathy, highlighting potential new therapeutic targets.
May inform future risk stratification in diabetes; leaves open validation and therapeutic targeting of these variants.
Our results indicate that 11 genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8, ADIPOQ and IL-10 showed significant positive association with diabetic nephropathy. Gene Ontology or pathway analysis showed that these genes may contribute to the pathophysiology of DN. The functional relevance of the variants and their pathways can lead to increased biological insights and development of new therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Nazir et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: